29 December 2021: Meta-Analysis
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
T A Manjunatha 1ABCDEF* , Rebecca Chng 1ABCDEF , Wai-Ping Yau 2ADEDOI: 10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
Table 2 Key baseline characteristics among primary publications of studies in which 1 or more of the treatment arms used Advagraf or Prograf.
| Study | Treatment arm | N | Mean age, years | Female, % | Mean BMI, kg/m2 | Diabetes, % | White, % | Black, % | Asian, % |
|---|---|---|---|---|---|---|---|---|---|
| Albano 2013 | TAC BID+MPA+CS | 309 | 50.80 | 31.7 | 25.4 | – | 95.8 | 2.3 | 1.9 |
| TAC QD_0.20+MPA+CS | 302 | 50.7 | 31.8 | 25.8 | – | 94.0 | 4.6 | 1.3 | |
| TAC QD_0.30+MPA+CS | 304 | 50.2 | 32.9 | 25.5 | – | 95.7 | 2.3 | 2 | |
| TAC QD_0.20+MPA+CS (+BAS) | 283 | 49.3 | 34.6 | 25.2 | – | 93.6 | 3.9 | 2.5 | |
| Anutrakulchai 2019 | TAC BID_0.10+MPA+CS | 63 | 40.68 | 31.7 | – | – | – | – | 100 |
| TAC BID_0.08–0.125+MPA+CS | 62 | 41.77 | 40.3 | – | – | – | – | 100 | |
| Arns 2017 | TAC BID (TacHexal)+MPA+CS | 35 | 47.9 | 17.1 | 27.6 | – | 94.3 | – | – |
| TAC BID (Prograf)+MPA+CS | 38 | 47.2 | 23.7 | 26.0 | – | 94.7 | – | – | |
| Asher 2014 | SRL QD+MPA+CS | 19 | 49 (median) | – | – | – | – | – | – |
| TAC BID+MPA+CS | 19 | 49 (median) | – | – | – | – | – | – | |
| Bakr 2018 | TAC BID+MPA+CS | 66 | 29.36 | 36.36 | – | – | – | – | – |
| TAC QD+MPA+CS | 33 | 29.88 | 36.36 | – | – | – | – | – | |
| Chen 2008 | CsA BID+SRL QD+CS | 20 | 40.2 | 65.00 | – | – | – | – | 100 |
| TAC BID+SRL QD+CS | 21 | 42.7 | 76.19 | – | – | – | – | 100 | |
| Cockfield 2019 | TAC QD_Low+ACEi/ARB | 71 | 50.5 | 33.8 | 27.6 | – | 78.9 | – | – |
| TAC QD_Low+OAH | 69 | 48.0 | 30.4 | 27.3 | – | 75.4 | – | – | |
| TAC QD_Std+ACEi/ARB | 71 | 50.4 | 33.8 | 28.3 | – | 81.7 | – | – | |
| TAC QD_Std+OAH | 70 | 52.4 | 30 | 27.0 | – | 81.4 | – | – | |
| De Graav 2017 | MPA+CS | 20 | – | 30 | – | – | 85.0 | 10.0 | 5 |
| TAC BID+MPA+CS | 20 | – | 20.0 | – | – | 80.0 | 10 | 10 | |
| Demirbas 2009 | CsA BID_Std+MPA+CS | 390 | 45.9 | 37.7 | – | 6.9 | 92.1 | 2.1 | 1.3 |
| CsA BID_Low+MPA+CS | 399 | 47.2 | 33.6 | – | 9.0 | 92.2 | 2.3 | 0.8 | |
| TAC BID_Low+MPA+CS | 401 | 45.4 | 34.2 | – | 8.5 | 94.0 | 1.0 | 0.7 | |
| SRL QD_Low+MPA+CS | 399 | 44.9 | 33.3 | – | 7.8 | 94.2 | 1.3 | 0.5 | |
| Ferguson 2011 | MPA+CS | 33 | 49.20 | 24.00 | – | – | 73.0 | 24.0 | – |
| SRL QD+CS | 26 | 52.70 | 23.00 | – | – | 89.0 | 12.0 | – | |
| TAC BID+MPA+CS | 30 | 53.60 | 27.00 | – | – | 77.0 | 17.0 | – | |
| Gaston 2009 | CNI_Low+MPA_Controlled+CS | 243 | 48.3 | 32.9 | – | – | 65.8 | 26.7 | – |
| CNI_Std+MPA_Controlled+CS | 237 | 48.8 | 32.9 | – | – | 70.9 | 24.5 | – | |
| CNI_Std+MPA_Fixed+CS | 240 | 49.6 | 32.1 | – | – | 69.6 | 25.8 | – | |
| Hamdy 2008 | SRL QD+MPA+CS | 67 | 31.8 | 29.9 | – | – | – | – | – |
| TAC BID+SRL QD+CS | 65 | 32.3 | 20.0 | – | – | – | – | – | |
| Harland 2019 | TAC BID+MPA+CS | 49 | 52.8 | 32.7 | 29.2 | – | 73.5 | 20.4 | 4.1 |
| BLES+MPA+CS | 46 | 51.1 | 34.8 | 28.5 | – | 78.3 | 19.6 | 2.2 | |
| TAC BID+BLES+CS | 44 | 52.4 | 31.8 | 28.6 | – | 70.5 | 25 | 4.5 | |
| Huh 2017 | TAC QD+MPA+CS | 75 | 46.00 | 29.30 | 22.5 | – | – | – | – |
| TAC QD+SRL QD+CS | 76 | 46.10 | 25.00 | 23.0 | – | – | – | – | |
| Kramer 2010a | TAC BID | 153 | 43.2 | 37.9 | – | – | – | – | – |
| TAC BID+MPA | 151 | 43.9 | 34.4 | – | – | – | – | – | |
| TAC BID+MPA+CS | 147 | 43.2 | 38.8 | – | – | – | – | – | |
| Kramer 2010b | TAC BID+MPA+CS | 336 | 45.50 | 36.00 | – | – | 81.3 | 5.7 | 2.1 |
| TAC QD+MPA+CS | 331 | 44.90 | 38.40 | – | – | 83.7 | 4.2 | 1.5 | |
| Langer 2012 | TAC BID_1.5–3 ng/mL+EVR BID+CS | 107 | 44.6 | 44.9 | – | – | 83.2 | 5.6 | 0 |
| TAC BID_4–7 ng/mL+EVR BID+CS | 117 | 46.9 | 41 | – | – | 83.8 | 0.9 | 1.7 | |
| Liu 2015 | CsA BID+MPA+CS | 36 | 43.00 | 27.78 | 22.1 | – | – | – | 100 |
| TAC BID+MPA+CS | 36 | 42.00 | 30.56 | 21.8 | – | – | – | 100 | |
| Tedesco-Silva 2014 | CsA BID+MPA+CS | 212 | 47.6 | 38.7 | – | 27.4 | 76.9 | 17.0 | 3.8 |
| TAC BID+MPA+CS | 212 | 48.6 | 35.8 | – | 28.3 | 71.7 | 24.1 | 2.4 | |
| TAC QD+MPA+CS | 214 | 47.8 | 35.5 | – | 23.4 | 74.8 | 19.2 | 2.3 | |
| Tsuchiya 2013 | TAC BID+MPA+CS | 52 | 46.10 | 32.70 | – | – | – | – | – |
| TAC QD+MPA+CS | 50 | 47.50 | 32.00 | – | – | – | – | – | |
| ACEi/ARB – angiotensin-converting enzyme inhibitor/angiotensin II receptor 1 blocker; BAS – basiliximab; BID – twice daily; BLES – bleselumab; BMI – body mass index; CNI – calcineurin inhibitor; CS – corticosteroid; CsA – cyclosporin A; EVR – everolimus; MPA – mycophenolic acid; OAH – other antihypertensive; QD – once daily; SRL – sirolimus; Std – standard dose; TAC – tacrolimus. | |||||||||